{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:26Z","timestamp":1793053706570,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is an epidemic of the modern age, and despite efforts to improve awareness, it remains the case that mortality has hardly altered over the decades, driven largely by late presentation. There is a strong public perception that male urinary symptoms is one of the key indicators of prostate cancer, and this continues to be part of messaging from national guidelines and media health campaigns. This narrative, however, is not based on evidence and may be seriously hampering efforts to encourage early presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Anatomically, prostate cancer most often arises in the peripheral zone, while urinary symptoms result from compression of the urethra by prostatic enlargement more centrally. Biopsy studies show that mean prostate volume is actually lower in men found to have (early) prostate cancer compared to those with benign biopsies. This inverse relationship between prostate size and the probability of cancer is so strong that PSA density (PSA corrected for prostate volume) is known to be significantly more accurate in predicting a positive biopsy than PSA alone. Thus, this disconnect between scientific evidence and the current perception is very striking. There is also evidence that using symptoms for investigating possible cancer may lead to higher proportions of men presenting with locally advanced or metastatic disease compared to PSA testing or screening programmes. Concerns about overwhelming health care services if men are encouraged to get tested without symptoms may also be overstated, with recent newer approaches to reduce over-investigation and treatment. In this article, we explore the link between urinary symptoms and prostate cancer and propose that public and professional messaging needs to change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>If rates of earlier diagnosis are to improve, we call for strong clear messaging that prostate cancer is a silent disease especially in the curable stages and men should come forward for testing regardless of whether or not they have symptoms. This should be done in parallel with other ongoing efforts to raise awareness including targeting men at highest risk due to racial ancestry or family history. While the current resurgence in interest and debate about prostate cancer screening is timely, change of this message by guideline bodies, charities and the media can be a first simple step to improving earlier presentation and hence cures rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02453-7","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T20:02:39Z","timestamp":1659556959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Urinary symptoms and prostate cancer\u2014the misconception that may be preventing earlier presentation and better survival outcomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Vincent J.","family":"Gnanapragasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Burnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2453_CR1","first-page":"393","volume":"1","author":"J Adams","year":"1853","unstructured":"Adams J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet. 1853;1:393\u20134.","journal-title":"Lancet."},{"key":"2453_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/1557988318798279","volume":"12","author":"HE Taitt","year":"2018","unstructured":"Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Men Health. 2018;12:807\u201323.","journal-title":"Am J Men Health"},{"key":"2453_CR3","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.","journal-title":"BMJ."},{"issue":"11","key":"2453_CR4","doi-asserted-by":"publisher","first-page":"894.e1","DOI":"10.1016\/j.crad.2019.06.004","volume":"74","author":"T Barrett","year":"2019","unstructured":"Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, et al. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. Clin Radiol. 2019;74(11):894.e1\u20139.","journal-title":"Clin Radiol."},{"key":"2453_CR5","volume-title":"Principles and practice of screening for disease","author":"JMG Wilson","year":"1968","unstructured":"Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968."},{"issue":"2","key":"2453_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2021.01.010","volume":"5","author":"AJ Vickers","year":"2022","unstructured":"Vickers AJ, Russo G, Lilja H, Evans C, Schalken JA, Klein E, et al. How should molecular markers and magnetic resonance imaging be used in the early detection of prostate cancer? Eur Urol Oncol. 2022;5(2):135\u20137.","journal-title":"Eur Urol Oncol."},{"issue":"538","key":"2453_CR7","doi-asserted-by":"publisher","first-page":"215709","DOI":"10.1016\/j.canlet.2022.215709","volume":"10","author":"A Papachristodoulou","year":"2022","unstructured":"Papachristodoulou A, Abate-Shen C. Precision intervention for prostate cancer: re-evaluating who is at risk. Cancer Lett. 2022;10(538):215709.","journal-title":"Cancer Lett."},{"issue":"10","key":"2453_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund M, J\u00e4derling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. STHLM3 consortium. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385(10):908\u201320.","journal-title":"N Engl J Med."},{"key":"2453_CR9","unstructured":"National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, NICE guideline [NG131]. 2021 update. Available from: https:\/\/www.nice.org.uk\/guidance\/ng131"},{"issue":"606","key":"2453_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3399\/bjgp13X660724","volume":"63","author":"J Hippisley-Cox","year":"2013","unstructured":"Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify men with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2013;63(606):e1\u201310.","journal-title":"Br J Gen Pract."},{"issue":"676","key":"2453_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3399\/bjgp18X699689","volume":"68","author":"J Just","year":"2018","unstructured":"Just J, Osgun F, Knight C. Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise? Br J Gen Pract. 2018;68(676):541\u20132.","journal-title":"Br J Gen Pract."},{"issue":"1","key":"2453_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1470-2045(19)30595-9","volume":"21","author":"MM Koo","year":"2020","unstructured":"Koo MM, Swann R, McPhail S, Abel GA, Elliss-Brookes L, Rubin GP, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 2020;21(1):73\u20139.","journal-title":"Lancet Oncol."},{"issue":"7","key":"2453_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/cncr.20126","volume":"100","author":"J Hugosson","year":"2004","unstructured":"Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100(7):1397\u2013405.","journal-title":"Cancer."},{"issue":"13","key":"2453_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320\u20138.","journal-title":"N Engl J Med."},{"issue":"1","key":"2453_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0090-4295(96)00360-3","volume":"49","author":"PI Karakiewicz","year":"1997","unstructured":"Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachab\u00e9 M, et al. Outcome of sextant biopsy according to gland volume. Urology. 1997;49(1):55\u20139.","journal-title":"Urology."},{"issue":"10","key":"2453_CR16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s11255-021-02892-w","volume":"53","author":"A Moolupuri","year":"2021","unstructured":"Moolupuri A, Camacho J, de Riese WT. Association between prostate size and the incidence of prostate cancer: a meta-analysis and review for urologists and clinicians. Int Urol Nephrol. 2021;53(10):1955\u201361.","journal-title":"Int Urol Nephrol."},{"issue":"3","key":"2453_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.euo.2018.09.001","volume":"2","author":"L Boesen","year":"2019","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, Balslev I, Bisbjerg R, Thestrup KC, et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7-10 prostate cancer in biopsy-na\u00efve men. Eur Urol Oncol. 2019;2(3):311\u20139.","journal-title":"Eur Urol Oncol."},{"issue":"4","key":"2453_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1073\/pnas.1815735116","volume":"116","author":"G Lorenzo","year":"2019","unstructured":"Lorenzo G, Hughes TJR, Dominguez-Frojan P, Reali A, Gomez H. Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth. Proc Natl Acad Sci U S A. 2019;116(4):1152\u201361.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2453_CR19","doi-asserted-by":"publisher","unstructured":"Lophatananon A, Light A, Burns-Cox N, et al. Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways. J Clin Urol. December 2021. doi:https:\/\/doi.org\/10.1177\/20514158211059057 (In Press)","DOI":"10.1177\/20514158211059057"},{"key":"2453_CR20","volume-title":"Bailey & Love\u2019s Short Textbook of Surgery","author":"AJH Rains","year":"1984","unstructured":"Rains AJH, Ritchie HD. Bailey & Love\u2019s Short Textbook of Surgery. 19th ed. London: HK Lewis; 1984.","edition":"19"},{"issue":"8","key":"2453_CR21","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/ijc.23713","volume":"123","author":"RM Martin","year":"2008","unstructured":"Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer. 2008;123(8):1924\u20138.","journal-title":"Int J Cancer."},{"issue":"5","key":"2453_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.10962.x","volume":"110","author":"M Fr\u00e5nlund","year":"2012","unstructured":"Fr\u00e5nlund M, Carlsson S, Stranne J, Aus G, Hugosson J. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of \u22653.0 ng\/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU Int. 2012;110(5):638\u201343.","journal-title":"BJU Int."},{"issue":"10","key":"2453_CR23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1464-410X.2008.07817.x","volume":"102","author":"SM Collin","year":"2008","unstructured":"Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008;102(10):1400\u20136.","journal-title":"BJU Int."},{"key":"2453_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/aje\/kwq493","volume":"173","author":"JM Schenk","year":"2011","unstructured":"Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173:1419\u201328.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2453_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21681805.2019.1703806","volume":"54","author":"J Chandra Engel","year":"2020","unstructured":"Chandra Engel J, Palsdottir T, Aly M, Egevad L, Gr\u00f6nberg H, Eklund M, et al. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA \u22653\u2009ng\/ml. Scand J Urol. 2020;54(1):1\u20136.","journal-title":"Scand J Urol."},{"issue":"3","key":"2453_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0302-2838(03)00200-8","volume":"44","author":"CC Schulman","year":"2003","unstructured":"Schulman CC, Kirby R, Fitzpatrick JM. Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol. 2003;44(3):294\u2013302.","journal-title":"Eur Urol."},{"issue":"706","key":"2453_CR27","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3399\/bjgp20X714137","volume":"71","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Coupland C. Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm. Br J Gen Pract. 2021;71(706):e364\u201371.","journal-title":"Br J Gen Pract."},{"issue":"6","key":"2453_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","volume":"80","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N'Dow J, S\u00f8nksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80(6):703\u201311.","journal-title":"Eur Urol."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02453-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T03:40:32Z","timestamp":1700883632000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2453"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02453-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There were no ethical issues or need for consent to participate needed for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give full consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}